Tianyin's Dr. James Jiayuan Tong is Invited to Speak at the CFO China Summit 2011 on January 19, 2011 at the St. Regis Hotel, Beijing

BEIJING, Nov. 16, 2010 /PRNewswire-Asia-FirstCall/ -- Dr. James Jiayuan Tong, Chief Financial Officer, Chief Business & Development Officer and Director of Tianyin Pharmaceutical (NYSE Amex: TPI) is invited to present at CFO China Summit 2011 which will be held at the St. Regis Hotel at 21 Jianguomenwai Avenue, Beijing 100020, China on January 19, 2011.

Dr. Tong will present in two panel discussions:

1. Implementing Effective Working Capital Management Strategies in China at 11:15 am
2. Understanding How CFOs in China Can Raise Funds through the Capital Markets at 12:00 noon

About the CFO China Summit 2011

The CFO China Summit 2011, held in Beijing on January 19th, 2011, is part of the successful CFO Asia Summit series that gathers leading financial drivers in China's economy to discuss key challenges currently faced by CFOs in China. Supported by the Wall Street Journal, this summit draws the top financial minds to discuss the core financial and organizational issues and develop effective strategies and solutions. The Summit will be held in a panel discussion format in order to ensure maximum engagement and interaction amongst the speakers and delegates, for enhanced idea generation and sharing of experiences gathered from their day-to-day work.

Key themes for the CFO China Summit 2011:

1. Financial risk management – Formulating strategies to minimize investment risks and generate higher returns on investments;
2. Working capital management – Ensuring healthy cash flow to finance growth in the business;
3. Talent management – Strategies to attract, train and retain qualified talent in the finance team;
4. Standardization of operating procedures in the finance function;
5. Ensuring sustainable growth amidst economic uncertainties – Developing approaches to buffer the changing economic policies for enhanced organizational stability.

More information regarding the Summit can be found on www.CFO-ChinaSummit.com

About Tianyin Pharmaceutical

Tianyin Pharmaceutical Co., Inc., headquartered at Chengdu, China, specializes in the development, manufacturing, marketing and sale of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. Tianyin currently manufactures and markets a comprehensive portfolio of 56 products, 23 of which are listed in the highly selective National Reimbursement List, 7 are included in the Essential Drug List of China. Tianyin has a pipeline of 10 products pending SFDA approval targeting cardiovascular conditions, women's health, immune system and respiratory disorders. Tianyin has an extensive nationwide distribution network with 730 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.